Testimonial What will make your funding application fly high and prevent it from crash-landing is ... accelopment!!
Dr. Theodossis Athanassios Theodossiou
FRINGE Project Coordinator, Lumiblast Project Partner
Oslo University Hospital, Norway

<< Projects


Fluorescence and reactive oxygen intermediates by neutron generated electronic excitation as a foundation for radically new cancer therapies

Deep lying tumours like aggressive brain cancer remain very difficult to treat and existing therapies offer only marginal increase in survival rates. In the case of photomedical therapies they are very effective, but mainly limited by their insufficient depth of light penetration into tissue. Current neutron-based therapies have sufficient penetration depth but suffer from lack of cancer specificity. In FRINGE we propose a genuinely new hybrid-technology. At its heart are chemical agents (photosensitisers – PS) which preferentially accumulate in the tumours especially in brain cancers where the blood brain barrier is compromised. The PSs designed for FRINGE will contain metal centres like Gadolinium (Gd), to enable interaction with incoming neutrons and facilitate the transfer of neutron energy into electron excitation of the PS, confirmed by concomitant fluorescence emission. Interaction with ambient oxygen will generate reactive oxygen species which will kill the tumour cells. The main scientific breakthrough of this project will be to establish experimental proof-of-principle of this novel neutron-activated therapy. FRINGE will combine the advantages of photomedical therapies (no mutagenic radiation) with the advantages of neutron-based therapies (large penetration depth). The externally-applied neutron beam can be energy-tuned to become therapeutic exactly at the depth of the tumour. Exploiting Gd as a contrast agent, FRINGE can also become a theranostic modality by use of magnetic resonance imaging. FRINGE has the potential of causing immunogenic cell death to cancers which could eliminate occult metastasis and act as a ‘cancer vaccine’. The highly interdisciplinary project team comprises world renowned experts from a unique combination of disciplines: Nuclear physicists, synthetic chemists, photochemists, photobiologists, medical physicists, quantum chemists and radio-oncologists will join forces to lay the foundations for a novel, curative cancer therapy.

Oslo University Hospital (OUS), NO



AreaLife Sciences
Duration01.11.2009 - 31.10.2013
Budget3.6 million euro


We have more than 25 years of experience in FP7, Horizon 2020 and other funding programmes, from finding the best funding scheme, to proposal writing, project management and communication. accelopment has the expertise and the staff to support you from the inception of your research and innovative idea to the management of your funded project. We will be your sparring partner through all the steps including choosing the right call and funding scheme, proposal writing, the negotiation of your grant with the European Commission (EC), and maximising the impact of your R&D project. We also like to share our experience and offer several targetted training options.t for the boxes



Brain cancer needs better treatment. I am thrilled to be involved in such a visionary project with highly motivated partners.

Dr. Jeanette Müller